A novel scheme for administering N-hydroxy-4-{2-[3-{N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in combination with a surgical, chemotherapy or hormone therapy treatment or with radiotherapy, for the treatment of cancer, characterized in that it is administered for 4 consecutive days, this period being followed by 3 consecutive days without any administration of the compound of formula (I), wherein it is understood that the chemotherapy treatment is not FOLFOX.
